292 related articles for article (PubMed ID: 38758750)
1. Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis.
Aung TM; Ngamjarus C; Proungvitaya T; Saengboonmee C; Proungvitaya S
PLoS One; 2024; 19(5):e0303337. PubMed ID: 38758750
[TBL] [Abstract][Full Text] [Related]
2. DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases.
Korshunov A; Shishkina L; Golanov A
Arch Pathol Lab Med; 2002 Sep; 126(9):1079-86. PubMed ID: 12204057
[TBL] [Abstract][Full Text] [Related]
3. Assessment of candidate immunohistochemical prognostic markers of meningioma recurrence.
Csonka T; Murnyák B; Szepesi R; Bencze J; Bognár L; Klekner A; Hortobágyi T
Folia Neuropathol; 2016; 54(2):114-26. PubMed ID: 27543769
[TBL] [Abstract][Full Text] [Related]
4. DNA topoisomerase IIα and mitosin expression predict meningioma recurrence better than histopathological grade and MIB-1 after initial surgery.
Winther TL; Torp SH
PLoS One; 2017; 12(3):e0172316. PubMed ID: 28301542
[TBL] [Abstract][Full Text] [Related]
5. The prognostic role of Ki-67/MIB-1 in meningioma: A systematic review with meta-analysis.
Liu N; Song SY; Jiang JB; Wang TJ; Yan CX
Medicine (Baltimore); 2020 Feb; 99(9):e18644. PubMed ID: 32118704
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Ki-67/MIB-1 Expression in Meningioma Patients: A Meta-Analysis.
Li J; Liang R; Song C; Xiang Y; Liu Y
Crit Rev Eukaryot Gene Expr; 2019; 29(2):141-150. PubMed ID: 31679269
[TBL] [Abstract][Full Text] [Related]
7. Tissue thioredoxin-interacting protein expression predicted recurrence in patients with meningiomas.
Cai Z; Zhang C; Zou Y; Lu C; Hu H; Qian J; Jiang L; Hu G
Int J Clin Oncol; 2017 Aug; 22(4):660-666. PubMed ID: 28243945
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
9. World Health Organization Grade II Meningioma: A 10-Year Retrospective Study for Recurrence and Prognostic Factor Assessment.
Champeaux C; Dunn L
World Neurosurg; 2016 May; 89():180-6. PubMed ID: 26850975
[TBL] [Abstract][Full Text] [Related]
10. High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma: A Comprehensive Meta-Analysis with 13,053 Patients Involved.
Luo Y; Zhang X; Mo M; Tan Z; Huang L; Zhou H; Wang C; Wei F; Qiu X; He R; Chen G
Medicine (Baltimore); 2016 Apr; 95(15):e3337. PubMed ID: 27082587
[TBL] [Abstract][Full Text] [Related]
11. Predicting outcomes of patients with intracranial meningiomas using molecular markers of hypoxia, vascularity, and proliferation.
Jensen R; Lee J
Neurosurgery; 2012 Jul; 71(1):146-56. PubMed ID: 22472549
[TBL] [Abstract][Full Text] [Related]
12. Microvascularization of Grade I meningiomas: effect on tumor volume, blood loss, and patient outcome.
Karsy M; Burnett B; Di Ieva A; Cusimano MD; Jensen RL
J Neurosurg; 2018 Mar; 128(3):657-666. PubMed ID: 28362240
[TBL] [Abstract][Full Text] [Related]
13. Value of KI-67/MIB-1 labeling index and simpson grading system to predict the recurrence of who grade I intracranial meningiomas compared to who grade II.
Prat-Acín R; Guarín-Corredor MJ; Galeano-Senabre I; Ayuso-Sacido A; Vera-Sempere F
J Clin Neurosci; 2021 Apr; 86():32-37. PubMed ID: 33775343
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for patients with World Health Organization grade III meningiomas treated at a single center.
Shan B; Zhang J; Song Y; Xu J
Medicine (Baltimore); 2017 Jun; 96(26):e7385. PubMed ID: 28658170
[TBL] [Abstract][Full Text] [Related]
15. Clinical and histopathological predictors of outcome in malignant meningioma.
Maier AD; Bartek J; Eriksson F; Ugleholdt H; Juhler M; Broholm H; Mathiesen TI
Neurosurg Rev; 2020 Apr; 43(2):643-653. PubMed ID: 30868425
[TBL] [Abstract][Full Text] [Related]
16. Combination of p53 and Ki67 as a Promising Predictor of Postoperative Recurrence of Meningioma.
Nagahama A; Yashiro M; Kawashima T; Nakajo K; Morisako H; Uda T; Naito K; Ichinose T; Ohata K; Goto T
Anticancer Res; 2021 Jan; 41(1):203-210. PubMed ID: 33419814
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.
Wu Y; Han Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Xu H; Wang Y; Ma F; Wang J; Xu B
Breast Cancer Res Treat; 2022 Jun; 193(2):381-392. PubMed ID: 35297009
[TBL] [Abstract][Full Text] [Related]
18. MCM7 expression is a promising predictor of recurrence in patients surgically resected for meningiomas.
Winther TL; Torp SH
J Neurooncol; 2017 Feb; 131(3):575-583. PubMed ID: 27868157
[TBL] [Abstract][Full Text] [Related]
19. Significance of COX-2 and VEGF expression in histopathologic grading and invasiveness of meningiomas.
Lee SH; Lee YS; Hong YG; Kang CS
APMIS; 2014 Jan; 122(1):16-24. PubMed ID: 23756256
[TBL] [Abstract][Full Text] [Related]
20. Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma.
Bruna J; Brell M; Ferrer I; Gimenez-Bonafe P; Tortosa A
Neuropathology; 2007 Apr; 27(2):114-20. PubMed ID: 17494511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
